| Identification | Back Directory | [Name]
Liarozole | [CAS]
115575-11-6 | [Synonyms]
Liarozole
1H-Benzimidazole, 6-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-
6-((3-chlorophenyl)(1H-imidazol-1-yl)methyl)-1H-benzo[d]imidazole
Retinoic acid receptors,Mesenchymal,R 75251,RAR/RXR,CYPs,Retinoid X receptors,R-75251,Imidazole,Ovariectomized,R75251,MCF-7,Liarozole,Cytochrome P450,Inhibitor,inhibit,SCID,Hydroxylation | [Molecular Formula]
C17H13ClN4 | [MDL Number]
MFCD00864664 | [MOL File]
115575-11-6.mol | [Molecular Weight]
308.76 |
| Chemical Properties | Back Directory | [Melting point ]
108.2° | [Boiling point ]
578.2±40.0 °C(Predicted) | [density ]
1.36±0.1 g/cm3(Predicted) | [solubility ]
DMSO: soluble | [form ]
A solid | [pka]
12.36±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Antipsoriatic. | [Definition]
ChEBI: Liarozole is a member of benzimidazoles. | [Brand name]
Liazal(Janssen). | [in vivo]
Liarozole (5-20 mg/kg; p.o.; 3 days) reverses the vaginal keratosis caused by estrogen stimulation[5].
Liarozole (40 mg/kg; p.o.; 21 days) reduces tumor burden substantially[6]. | Animal Model: | Ovariectomized rats[5] | | Dosage: | 5~20 mg/kg | | Administration: | P.o.; 3 days | | Result: | Reversed the vaginal keratosis caused by estrogen stimulation. |
| Animal Model: | SCID mice[6] | | Dosage: | 40 mg/kg | | Administration: | P.o.; 21 days | | Result: | Inhibited tumor growth and survival. |
| [IC 50]
CYP26: 7 μM (IC50) |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|